After surgery, patients were treated with the aforementioned drugs used as single agents.

Introducing the polypill dominates a strategy of a 4-drug regimen with the aforementioned drugs and statins.

For those patients who achieve a remission following the use of one of the aforementioned drugs, bone marrow transplantation is recommended.

In principle, controlled release of the aforementioned drugs can be achieved by biodegradation of the polymer or by cleavage of covalently bound polymer-drug conjugates.